Table 2. Characteristics of a select group of subjects with measurements of erythrocyte-bound apolipoprotein B (ery-apoB) and ABO blood group phenotype.
| A (N = 39) | B (N = 6) | AB(N = 8) | O (N = 51) | P-value | |
| Age (years) | 61.7±9.5 | 56.7±16.7 | 67.6±8.6 | 61.7±9.3 | 0.23 |
| Male gender (n, %) | 24 (61.5) | 3 (50.0) | 5 (62.5) | 31 (60.8) | 0.96 |
| History of T2DM (n, %) | 9 (23.1) | 0 (0.0) | 3 (37.5) | 10 (19.6) | 0.38 |
| History of CVD (n, %) | 27 (69.2) | 4 (66.7) | 7 (87.5) | 39 (76.5) | 0.67 |
| Use of statins (n, %) | 27 (69.2) | 5 (83.3) | 8 (100.0) | 41 (80.3) | 0.30 |
| BMI (kg/m2) | 27.0±5.2 | 28.3±4.2 | 27.9±3.8 | 27.1±5.0 | 0.92 |
| Hemoglobin (mmol/l) | 8.8±0.8 | 8.9±0.6 | 8.5±1.1 | 8.9±0.8 | 0.72 |
| Erythrocytes (*1012/l) | 4.6±0.4 | 4.7±0.4 | 4.4±0.6 | 4.6±0.4 | 0.53 |
| Leukocytes (*109/l) | 7.1±1.6 | 6.1±1.2 | 6.8±1.0 | 6.5±1.6 | 0.22 |
| Platelets (*109/l) | 235±56 | 237±48 | 252±63 | 226±45 | 0.55 |
| C-reactive protein (mg/l) | 3.4±3.9 | 1.8±1.0 | 2.7±2.5 | 2.2±1.8 | 0.34 |
| Ery-apoB (a.u.) | 0.89±1.15* | 0.73±1.12* | 0.69±0.69* | 1.56±0.94*** | <0.001 |
| Total cholesterol (mmol/l) | 4.7±1.0 | 4.4±1.3 | 4.1±0.8 | 4.4±0.9 | 0.18 |
| LDL-C (mmol/l) | 2.7±0.9* | 1.9±1.0 | 2.3±0.6 | 2.2±0.8** | 0.04 |
| HDL-C (mmol/l) | 1.34±0.37 | 1.63±0.65 | 1.30±0.41 | 1.42±0.46 | 0.41 |
| Triglycerides (mmol/l) | 1.65±0.85 | 1.88±1.83 | 1.09±0.60 | 1.76±1.11 | 0.36 |
| Apolipoprotein B (g/l) | 0.91±0.24 | 0.75±0.24 | 0.80±0.18 | 0.82±0.19 | 0.12 |
| Apolipoprotein AI (g/l) | 1.57±0.29 | 1.57±0.27 | 1.52±0.30 | 1.60±0.35 | 0.90 |
Subjects were divided according to ABO blood group phenotype.
*
Significantly different when compared to blood group O (P<0.05).
**
Significantly different when compared to blood group A (P<0.05).
***
Significantly different when compared to blood group A, B or AB (all P<0.05).